Recursion Pharmaceuticals' Q2 2025 10-Q filing provides insight into the potential financial implications of the two pending lawsuits. While these legal disputes represent inherent risks, the company's current assessment indicates no probable material financial impact as of the reporting period.
Here's a breakdown of the disclosed lawsuits and their current financial standing:
- Exscientia Class Action Lawsuits: These involve putative class action complaints filed against Exscientia plc (which Recursion subsequently acquired) and its officers. The complaints, consolidated and with a motion to dismiss pending, allege violations of federal securities laws and seek unspecified compensatory damages and attorneys' fees.1 As of June 30, 2025, Recursion has not recorded any liability for these cases, as an unfavorable outcome was deemed "not probable".1
- Landlord Dispute (Industry Office SLC, LLC): This lawsuit stems from a lease agreement for laboratory and office space, with the landlord alleging anticipatory repudiation, breach of contract, and breach of the implied covenant of good faith and fair dealing, seeking monetary damages and attorney's fees. Recursion has filed counterclaims alleging breach of contract and fraudulent misrepresentation.1 Similar to the Exscientia cases, as of June 30, 2025, Recursion had recorded no liability, considering an unfavorable outcome "not probable".1
It's important to note that while the company currently assesses an unfavorable outcome as not probable, the 10-Q explicitly states that "An unfavorable resolution of any such matter could materially affect the Company’s future financial position, results of operations or cash flows".1 This highlights that legal proceedings always carry a degree of uncertainty and potential future risk, even if not immediately probable. Investors can monitor future 10-K and 10-Q filings for updates on these cases and any changes in the company's assessment.
For further details, Fintel's SEC Filings page for RXRX provides direct access to these documents and subsequent filings.2
